- CMS finalized a 2.48% Medicare Advantage rate increase for 2026 — far better than the initial near-zero proposal that wiped $100B from insurer valuations — but still only about half of actual medical cost growth, and CMS warned the “days of unlimited increases must end”
- Trump unveiled tariffs of up to 100% on select patented brand-name drugs, with exemptions for companies committing to U.S. manufacturing or agreeing to most-favored-nation pricing; the EU and Japan face a capped 15% rate, while the UK secured a lower rate by pledging to double government drug spending
- Novo Nordisk priced its new high-dose Wegovy at $399/month for cash-pay patients — roughly 40% less than Lilly’s top three Zepbound doses — while a Nature study found a specific gene variant predicts both stronger weight loss and more side effects from GLP-1 drugs
- Gilead Sciences agreed to acquire German biotech Tubulis for up to $5B (antibody-drug conjugates for cancer), and Neurocrine Biosciences will pay $2.9B for Soleno Therapeutics to gain Vykat XR, a drug treating the insatiable hunger of Prader-Willi syndrome
What Happened?
It was a consequential week across every corner of U.S. healthcare. The Trump administration’s CMS finalized a 2.48% Medicare Advantage rate increase for 2026 — far above the near-zero initial proposal that had triggered a $100 billion wipeout in insurer stocks — sending shares surging by double digits. At the same time, the administration announced tariffs of up to 100% on select patented brand-name drugs, with carve-outs for manufacturers committing to domestic production. Insurers eliminated approximately 11% of their prior-authorization requirements, potentially sparing 6.5 million patients from administrative delays annually. On the deal front, Gilead Sciences agreed to pay up to $5 billion for German biotech Tubulis to build out its antibody-drug conjugate cancer pipeline, while Neurocrine Biosciences announced a $2.9 billion acquisition of Soleno Therapeutics for its Prader-Willi syndrome drug.
Why It Matters?
The Medicare Advantage rate revision is both a short-term relief and a long-term warning. CMS director Chris Klomp was direct: even at 2.48%, the increase is about half of actual medical cost growth, and the agency is signaling that the era of large annual payment bumps is over. Drug tariffs add another pressure point — brand-name manufacturers face a binary choice between absorbing the tariff, moving production to the U.S., or accepting government price benchmarking. Novo Nordisk’s aggressive Wegovy pricing — $399/month, well below Lilly’s Zepbound — escalates the GLP-1 price war and could reshape which obesity drugs dominate pharmacy shelves. And the new Nature study linking gene variants to GLP-1 response opens the door to precision medicine in obesity treatment, potentially transforming how these blockbuster drugs are prescribed.
What’s Next?
Insurers must decide by April 20 whether to join the optional Medicare program for weight-loss drug coverage — a decision complicated by a JAMA analysis finding the coverage would cost insurers billions, with negotiated savings covering only 4.4% of newly eligible patients. Long Covid adds another long-run cost overhang: OECD economies are projected to absorb up to $135 billion annually over the next decade through healthcare costs and lost productivity. The drug tariff framework will face legal and diplomatic challenges, and the full impact on pharmaceutical supply chains — many of which are heavily reliant on overseas manufacturing — will take months to fully emerge.
Source: Bloomberg Health Monitor
